Trial Profile

A phase IIb clinical trial of nimacimab with ENHANZE for treatment of obesity

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 14 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Jan 2026 New trial record
12 Jan 2026 According to a Skye Bioscience media release, Phase 2b (CBeyond 2) plan will be finalized and aligned with regulators, including completion of a Type C meeting in Q1 2026, with initiation of the adaptive design Phase 2b clinical trial expected in Q3 2026.
05 Jan 2026 According to a Skye Bioscience media release, company plans to initiate a phase IIb clinical trial in obesity in mid-2026, supported by a non-exclusive global collaboration and license agreement enabling higher-dose subcutaneous administration of Nimacimab.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com